Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers

Shi-Han Yang, Can-Tong Liu, Chao-Qun Hong, Ze-Yuan Huang, Huan-Zhu Wang, Lai-Feng Wei, Yi-Wei Lin, Hai-Peng Guo, Yu-Hui Peng, and Yi-Wei Xu

1Department of Dermatology and Venereology, Affiliated Shantou Hospital of Sun Yat-sen University, 114 Waima Road, Shantou 515041, China
2Department of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou 515041, China
3Precision Medicine Research Center, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China
4Department of Oncological Laboratory Research, The Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou 515041, China
5Department of Head and Neck Surgery, The Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou 515041, China
6Guangdong Esophageal Cancer Research Institute, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China

Correspondence should be addressed to Hai-Peng Guo; ghaipeng@sina.cn, Yu-Hui Peng; pengyuhui666@163.com, and Yi-Wei Xu; yiwei512@126.com

Received 19 February 2021; Accepted 31 May 2021; Published 12 July 2021

1. Introduction

Skin cancer is the most common type of carcinoma, categorized as melanoma and nonmelanoma skin cancer (NMSC). Except for the Merkel cell carcinoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the other two predominant histological types of NMSC [1]. Skin BCC, originating from cells in the interfollicular epidermis or upper infundibulum, accounted for about 80% of NMSCs [2]. Compared with the general population, patients with a history of skin BCC had a 3-year cumulative risk of 44% and a tenfold increase in recurrence [3, 4]. As the second most common NMSC, patients with early-stage skin SCC have 5-year disease-specific survival of more than 75%.
However, for those with lymph node metastasis, the 5-year overall survival is lower than 50%, and it is mostly lower than 10% when distant metastasis happens [5]. The diagnosis of skin cancer is mainly based on pathology; thus, it is necessary to explore some serological indicators to assist the diagnosis.

Tumor-associated antigens (TAAs) can not only be overexpressed in cancer tissues but also be secreted into peripheral blood, which might be the basis of distant metastasis [6]. After recognizing TAAs, the immune system can secrete specific autoantibodies [7]. In the last decade, numerous studies focused on the diagnostic value of serum autoantibodies against TAAs in different cancers, especially in the early detection [8–11]. When it came to skin cancers, most of the related research paid attention to melanoma, but not NMSC [12–14]. Whether serum autoantibodies have a potential diagnostic value for NMSC needs to be addressed.

In this study, we assessed the diagnostic value of an autoantibody panel against three well-recognized TAAs in skin SCC and BCC, including p53, matrix metalloproteinase-7 (MMP-7), and heat shock protein 70 (Hsp70). Encoded from TP53, a tumor-suppressor gene, p53 was described as the first antigen to elicit autoantibodies in cancer [15]. From then on, there was an increase in research about autoantibodies against p53 in cancers, such as lung [16], esophageal [17], and oral cancer [18]. Autoantibodies against matrix metalloproteinase-7 (MMP-7), a member of the matrix metalloproteinase family, were also found in many cancers, including esophageal [17] and oral squamous cell carcinoma [19]. The last antigen, Hsp70, a highly immunogenic antigen, has been shown to induce an autoantibody response in several cancers [20].

### 2. Materials and Methods

#### 2.1. Experimental Subjects

Serum samples were collected from participants diagnosed pathologically with skin cancers, who were recruited from the Cancer Hospital of Shantou University Medical College between November 2014 and January 2020. The noneligible skin cancer standards for the study were set as follows: tumors with any other pathological types including melanoma and dermatofibrosarcoma or without concise pathological types and patients who suffered from other malignancies before. Normal controls were comprised of healthy volunteers who had evidence of tumor inexistence. Approval from the Institutional Ethics Committee of the Cancer Hospital of Shantou University Medical College and written consent from each participant was obtained. The study conformed to the provisions of the Declaration of Helsinki.

The clinicopathological data of these participants were also collected for further study, including age, gender, histological type, site of tumor, and TNM stage. TNM stage was evaluated according to the 8th edition published by the Union for International Cancer Control for skin cancer staging [21]. In the present study, tumors with stage I or II were defined as early-stage skin cancers, and tumors with stage III or IV were considered an advanced stage. Peripheral blood samples were collected before anticancer treatments, clotted at room temperature for 30 min, and centrifuged at 1250 g for 5 min. Then, the sera were removed and stored at -80°C in the biobank until the experiment began.

#### 2.2. Recombinant Protein Expression

The coding sequence regions for P53 (NM_001276760.1), MMP-7 (NM_002423.3), and HSP70 (NM_005345.5) were subcloned into the pDEST17 expression vector (Invitrogen, Waltham, MA). The expression, purification, and analysis of these recombinant proteins were conducted as described in our previous studies [17].

#### 2.3. Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA was performed as previously described by SH Yang and CT Liu, who were blinded to all patient information [17]. Briefly, purified recombinant antigens of p53, MMP-7, and Hsp70 were diluted in 50 mM bicarbonate buffer. Serum samples and quality control samples (a pooled serum sample collected randomly from 50 cancer patients) were diluted at 1:110 in blocking buffer and were then incubated at 37°C for one hour, as well as the control rabbit polyclonal antibodies. After washing for three times, horseradish peroxidase-conjugated goat anti-rabbit IgG or anti-human IgG (Santa Cruz Biotechnology, Santa Cruz, CA) was added as the secondary antibody. After one-hour incubation and washing again, 3,3′,5,5′-tetramethylbenzidine (TMB) and hydrogen peroxide were added for color formation. The absorbance of each well was read at 450 nm and referenced to 630 nm by a plate microplate reader (Thermo Fisher Scientific, Boston, USA) in five minutes. All serum sample detections were conducted in duplicate.

#### 2.4. Oncomine Database Analysis

We obtained RNA-sequencing data of p53, MMP-7, and Hsp70 gene expression from Oncomine, which were comprised of 15 skin BCC samples, 11 skin SCC samples, and 4 normal samples [22]. The heat map and box plot were conducted to compare their expressions.

#### 2.5. Statistical Analysis

All analyses were produced with IBM SPSS Statistics 24 (SPSS Inc., Chicago, IL, USA), GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA), and R package 3.6.1. The Mann–Whitney U test was used for comparing the level of different markers between the normal group and the skin cancer group and between the SCC group and the BCC group. We applied logistic regression analysis to construct a predicted probability (P) of being diagnosed with skin cancer as one marker from the three autoantibodies. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic boundaries including the area under the ROC curve (AUC) with the 95% confidence interval (CI). The maximum sensitivity was achieved when the specificity was set at more than 90%. For the clinical diagnosis practice of tumor markers, the sensitivities with 95% specificities were also shown. We compared positive rates of the autoantibody panel before and after surgical resection in skin cancer patients with Fisher’s exact test. The heatmap R package was applied to plot the expression heat map of mRNAs in different patients. In this study, $P < 0.05$ in two tails was seen as statistically significant.
3. Results

3.1. Patient Characteristics. As shown in Figure 1, after eliminating 29 patients including 12 with melanoma, 4 with dermatofibrosarcoma, 5 with other tumors when being diagnosed or before diagnosis, and 8 without pathological diagnosis, 101 NMSCs and 102 normal controls were recruited into our study. There were 67 patients with SCC (66.3%) and 34 patients with BCC (33.7%) in this NMSC group. Patients with stages I and II accounted for 33/101 and 36/101, respectively (Table 1).

3.2. Serum Autoantibody Level. As illustrated in Figure 2(a), the levels of these three autoantibodies were statistically higher in the skin cancer groups than those in the normal groups (p53 and Hsp70: both $P < 0.001$; MMP-7: $P < 0.01$). In order to define the specificity in distinguishing SCC and BCC, we made a comparison of these autoantibody levels between SCC and BCC. However, there was no statistical significance between them (Figure 2(b)).

3.3. The Three-Autoantibody Panel for Detection of NMSC. Autoantibodies against p53, MMP-7, and Hsp70 were all identified to be valid predictors, with the $P$ value calculated by $\ln \left[ \frac{P}{1 - P} \right] = 10.347 \times (p53) + 5.590 \times (MMP-7) + 9.483 \times (Hsp70) - 2.828$. Then, the $P$ value was applied to draw the ROC curve. From ROC analysis (Figure 3), with the specificity of over 90%, autoantibodies against p53 acquired an AUC value of 0.799 (95% CI: 0.739-0.859) in distinguishing NMSCs from normal controls with the sensitivity of 48.5% (Table 2), while the AUC of autoantibodies against MMP-7 and Hsp70 was 0.621 and 0.719, respectively, with sensitivities of 34.7% and 31.7%. When combining these three biomarkers into a panel, we got the AUC value of the panel improving to 0.841 (95% CI: 0.788-0.894) with the sensitivity of 60.4% and the specificity of 91.2% when differentiating the NMSC group from the normal control group. Furthermore, this three-autoantibody panel had a great AUC (0.851, 95% CI: 0.793-0.908) and moderate sensitivity (59.4%) to diagnose early-stage NMSC patients. Great diagnostic values were also observed in different histological types. Meanwhile, we assessed the diagnostic performance of this panel when the specificity was set at 95.0%, and we found that the sensitivities of our panel remained high for the diagnosis of NMSC and early-stage NMSC (Table 2). These results indicated the robustness of this four-autoantibody panel. To conclude, this panel might be a potential biomarker for distinguishing NMSC patients from normal controls.

3.4. Level of the Three-Autoantibody Panel after Surgical Treatment. We selected 7 NMSC patients with positive results of the three-autoantibody panel before surgery, and we compared the changes in postoperative levels at four weeks. The results showed that the panel became negative at postoperation in 5 cases ($5/7, P < 0.05$). As shown in Figure 4, the levels of autoantibodies against p53 and MMP-7 showed a descending trend after surgical resection of primary tumors, compared with the corresponding preoperative samples. However, for the Hsp70 autoantibody, it seems that the levels did not change after surgery (Figure 4). There is a great need to further explore the monitoring treatment effect of the single autoantibody or the panel for NMSC in a large sample set.

3.5. Correlation between Autoantibodies and Clinicopathological Variables. We next evaluated the relationship of the serum levels of autoantibodies against p53, MMP-7, and Hsp70 with clinicopathological features in NMSCs (Figure 5). However, there were no significant associations between the serum levels of autoantibodies with clinicopathological variables examined, including age, gender, histological types, invasion depth, lymph node status, and early- and advanced-stage groups ($P > 0.05$).

3.6. mRNA Levels of p53, MMP-7, and Hsp70 from Oncomine. In order to further evaluate the levels of mRNA of p53, MMP-7, and Hsp70, we explored the datasets of skin SCC and BCC in Oncomine, and the levels of mRNA in tissues were visually shown in the heat map (Figure 6(a)). As exhibited in Figure 6(b), the p53 mRNA level was significantly higher in BCC than in normal skin ($P < 0.05$), while the Hsp70 mRNA level was higher in SCC ($P < 0.001$). However, there was no significant difference of the MMP-7 mRNA level between BCC or SCC and normal skin.

4. Discussion

In this study, we conducted a three-autoantibody panel to evaluate its diagnostic value in NMSC, including skin SCC and BCC. As the results showed, the serum levels of autoantibodies against p53, MMP-7, and Hsp70 were all higher in NMSC patients than in normal controls. ROC curve illustrated that the AUC of the three-autoantibody panel was larger than that of a single autoantibody, and the meaningful diagnostic efficacy of the autoantibody panel in early-stage tumors could also be found. Through exploring the RNA-
sequence data in Oncomine, we found that p53 and Hsp70 mRNAs were upregulated in BCC and SCC, respectively.

Autoantibodies against p53 have been detected as overexpression in several tumors [16–18]. In our study, the level of autoantibodies against p53 was higher in NMSC when compared with that of the normal controls. However, Moch et al. found the discrepant result that there was no difference of the level of p53 autoantibodies between skin cancers and

### Table 1: Details of the NMSC patients and normal controls.

| Test parameter            | Category                  | NMSC (n = 101) | Normal (n = 102) |
|---------------------------|---------------------------|----------------|-----------------|
|                           | Cases                     | %             | Cases           |
| Gender                    | Male                      | 56            | 50              |
|                           | Female                    | 45            | 52              |
|                           | ≤60                       | 16            | —               |
|                           | 61-70                     | 26            | —               |
|                           | 71-80                     | 37            | —               |
|                           | 81-100                    | 22            | —               |
| Age at enrollment (years) | Face/scalp/forehead       | 50            | —               |
|                           | Nose/ear/lip/eyelid       | 31            | —               |
|                           | Leg/arm/hand              | 10            | —               |
|                           | Others                    | 10            | —               |
| Histological type         | Squamous cell carcinoma   | 67            | —               |
|                           | Basal cell carcinoma      | 34            | —               |
| Site of tumor             | Face/scalp/forehead       | 50            | —               |
|                           | Nose/ear/lip/eyelid       | 31            | —               |
|                           | Leg/arm/hand              | 10            | —               |
|                           | Others                    | 10            | —               |
| T category                | T1                        | 32            | —               |
|                           | T2                        | 37            | —               |
|                           | T3                        | 21            | —               |
|                           | T4                        | 11            | —               |
| Lymph node metastasis     | Positive                  | 9             | 8.9%            |
|                           | Negative                  | 92            | 91.1%           |
| TNM stage                 | I                         | 33            | 32.7%           |
|                           | II                        | 36            | 35.6%           |
|                           | III                       | 17            | 16.8%           |
|                           | IV                        | 15            | 14.9%           |

Note: NMSC: nonmelanoma skin cancer.

![Figure 2: Serum autoantibody measurements in study subjects.](a)

![Figure 2: Serum autoantibody measurements in study subjects.](b)

Figure 2: Serum autoantibody measurements in study subjects. (a) The OD values of autoantibodies against p53, MMP-7, and Hsp70 were detected from patients with NMSCs and normal controls. (b) The levels of autoantibodies against p53, MMP-7, and Hsp70 were shown in squamous cell carcinoma and basal cell carcinoma. ns: no statistical significance.
The AUC of the p53 autoantibody in our study was 0.799 (95% CI: 0.739-0.859) in NMSCs and 0.819 (95% CI: 0.754-0.885) in early-stage NMSCs with a slightly improved sensitivity of 49.3% compared with the former (48.5%), indicating the potential value of anti-p53 in distinguishing NMSCs from normal controls. Accumulating evidence highlighted serum p53 autoantibodies as a broad-spectrum biomarker in early detection of cancer, with the AUCs ranging from 0.627 to 0.781 [8, 24–28]. A recent study including 182 stage 0/1 breast cancer patients showed a positive rate of 10% for the p53 autoantibody [29]. Another study with the use of a new electrochemiluminescence immunoassay indicated that p53 autoantibodies were helpful in detecting esophageal and colorectal cancers with high specificity [30]. As we know, there were some researches about the diagnostic value of autoantibodies against MMP-7 and Hsp70 in other cancers but not in skin cancers. Jiang et al. found that the sensitivity of MMP-7 autoantibodies for diagnosing early-stage oral cancers was 48.6% and the AUC was 0.761 [19]. In the upper gastrointestinal neoplasms, the AUC of MMP-7 autoantibodies was varied from 0.597 to 0.870 [23, 31]. Zhong et al. found an improved level of serum Hsp70 autoantibodies in non-small-cell lung cancer patients with a diagnostic AUC of 0.731, a sensitivity of 0.74, and a
It was reported that the AUCs of autoantibodies against Hsp70 were 0.652 in esophagogastric junction cancer [24] and 0.765 in nasopharyngeal carcinoma [27]. These similar diagnostic values were found in our study. Thus, although our study showed the diagnostic value of any single autoantibody, these autoantibodies were not limited to NMSCs.

A single autoantibody might lack plenty of sensitivity and specificity for diagnosis, while a panel of autoantibodies might overwhelm this problem [33, 34]. Identification of new serum biomarkers for cancer diagnosis is an important means to improve clinical efficacy, especially for the early-stage malignancies [35]. Previous reports of other tumors have highlighted the potential value of autoantibody panels [17, 24]. For example, in our previous research, the AUC of autoantibodies against a panel of six TAAs (p53, NYESO-1, PRDX6, MMP-7, Hsp70, and BMI-1) might improve to 0.786 with a sensitivity of 50.0% and a specificity of 90.5% in the diagnosis of early-stage esophagogastric adenocarcinoma when compared with the individuals [24]. There were less studies published about the early diagnostic value of an autoantibody panel in NMSCs. Herein, our study might be the first one to explore the diagnostic value of a panel of autoantibodies against p53, MMP-7, and Hsp70 in the skin SCC and BCC. In early-stage SCC and BCC of this study, the AUC and sensitivity of the panel showed great discrimination from normal controls (AUC: 0.851 (95% CI: 0.793-0.908); sensitivity: 59.40%), which indicated that this panel might be the potential early detection marker of NMSCs in future clinical practices.

### Table 2: Diagnostic values for the individual autoantibodies and the autoantibody panel in NMSC.

|                          | AUC             | SEN             | SPE             | PPV             | NPV             | PLR             | NLR             |
|--------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **All stages of NMSC**   |                 |                 |                 |                 |                 |                 |                 |
| p53 autoantibody         | 0.799 (0.739-0.859) | 48.5%/40.6%   | 90.2%/95.0%     | 83.1%/89.2%     | 63.8%/61.7%     | 4.95/8.29       | 0.57/0.63       |
| MMP-7 autoantibody       | 0.621 (0.543-0.699) | 34.7%/31.7%   | 91.2%/95.0%     | 79.6%/86.5%     | 58.5%/58.4%     | 3.94/6.47       | 0.72/0.72       |
| Hsp70 autoantibody       | 0.719 (0.649-0.789) | 31.7%/29.7%   | 93.1%/95.0%     | 82.0%/85.7%     | 57.9%/57.7%     | 4.59/6.06       | 0.73/0.74       |
| The autoantibody panel   | 0.841 (0.788-0.894) | 60.4%/51.5%   | 91.2%/95.0%     | 87.2%/91.2%     | 69.9%/66.4%     | 6.86/10.51      | 0.43/0.51       |
| **Early-stage of NMSC**  |                 |                 |                 |                 |                 |                 |                 |
| p53 autoantibody         | 0.819 (0.754-0.885) | 49.3%/43.5%   | 90.2%/95.0%     | 77.3%/85.8%     | 72.4%/70.3%     | 5.03/8.88       | 0.56/0.59       |
| MMP-7 autoantibody       | 0.627 (0.536-0.718) | 37.7%/33.3%   | 91.2%/95.0%     | 74.4%/82.2%     | 68.4%/67.8%     | 4.28/6.80       | 0.68/0.70       |
| Hsp70 autoantibody       | 0.746 (0.673-0.820) | 31.9%/30.4%   | 93.1%/95.0%     | 75.8%/80.8%     | 66.9%/66.8%     | 4.62/6.20       | 0.73/0.73       |
| The autoantibody panel   | 0.851 (0.793-0.908) | 59.4%/52.2%   | 91.2%/95.0%     | 82.1%/87.8%     | 76.8%/74.6%     | 6.75/10.65      | 0.45/0.50       |
| **Skin squamous cell carcinoma** |               |                 |                 |                 |                 |                 |                 |
| p53 autoantibody         | 0.790 (0.719-0.860) | 47.8%/38.8%   | 90.2%/95.0%     | 76.2%/83.8%     | 72.5%/70.3%     | 4.88/7.92       | 0.58/0.64       |
| MMP-7 autoantibody       | 0.616 (0.524-0.708) | 34.3%/32.8%   | 91.2%/95.0%     | 71.8%/81.4%     | 67.9%/68.3%     | 3.90/6.69       | 0.72/0.71       |
| Hsp70 autoantibody       | 0.697 (0.616-0.777) | 28.4%/25.4%   | 93.1%/95.0%     | 73.0%/77.3%     | 66.5%/66.0%     | 4.12/5.18       | 0.77/0.78       |
| The autoantibody panel   | 0.826 (0.761-0.891) | 56.7%/49.3%   | 91.2%/95.0%     | 80.9%/86.8%     | 76.3%/74.1%     | 6.44/10.06      | 0.48/0.53       |
| **Skin basal cell carcinoma** |             |                 |                 |                 |                 |                 |                 |
| p53 autoantibody         | 0.818 (0.736-0.900) | 50.0%/44.1%   | 90.2%/95.0%     | 63.0%/85.5%     | 84.4%/72.2%     | 5.10/9.00       | 0.55/0.59       |
| MMP-7 autoantibody       | 0.631 (0.509-0.753) | 35.3%/29.4%   | 91.2%/95.0%     | 57.2%/79.7%     | 80.9%/67.3%     | 4.01/6.00       | 0.71/0.74       |
| Hsp70 autoantibody       | 0.763 (0.672-0.854) | 38.2%/38.2%   | 93.1%/95.0%     | 64.9%/83.6%     | 81.9%/70.1%     | 5.54/7.80       | 0.66/0.65       |
| The autoantibody panel   | 0.870 (0.803-0.937) | 67.6%/55.9%   | 91.2%/95.0%     | 71.9%/88.2%     | 89.4%/76.7%     | 7.68/11.41      | 0.35/0.46       |

Note: data after “/” were obtained at a specificity of 95.0%. NMSC: nonmelanoma skin cancer; AUC: the area under the receiver operating characteristic curve; SEN: sensitivity; SPE: specificity; PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio.
Autoantibodies are secreted by the immune system after they have recognized antigens, which might be produced by abnormal transcription or modification of a gene, like histone acetylation [36]. The synchronous increases of autoantibodies and mRNAs were observed in several cancers, for instance, BMI-1 in cervical carcinoma [37] and FKBP52 in breast cancer [38]. In skin cancers, some related researches were also conducted. Moch et al. found the presence of a mutation of the p53 gene in skin BCC and SCC, but the low levels of serum p53 autoantibodies were detected [23]. Unlike these publications, in our study, we found that the levels of p53 autoantibodies were high both in skin BCC and SCC (P < 0.001), and data from Oncomine showed that the p53 mRNA level was significantly higher in BCC than in normal skin (P < 0.05). It could be suspected that the inconsistency might be due to the different races, and the production of p53 autoantibodies might not be associated with gene mutation in skin BCC. As for Hsp70, data from Oncomine showed the upregulated Hsp70 mRNA level in skin SCC (P < 0.001). Wood et al. observed the overexpression of Hsp70 autoantigens in skin SCC [39], and our study also found a higher level of Hsp70 autoantibodies of skin SCC when compared with that of normal participants (P < 0.001), which might indicate the vital role of Hsp70 in the tumorigenesis of skin SCC. Recently, two studies showed that Hsp70 and Hsp90 are beneficial to the reverse regulation of p53 conformation and activity in the cell environment. Through the cycle of the molecular chaperone mechanism, p53 is constantly reconstituted, and its active state is related to the stress state of cells, so that p53 can make a rapid response to the changes of the cell environment to prevent irreversible degradation in an extreme environment [40, 41]. Based on the upregulation of p53 mRNA in BCC and Hsp70 mRNA in SCC compared with normal skin, we speculated that the different status of p53 driven by Hsp70 and Hsp90 might hint of the different histological types of NMSC. Thus, the association between p53 and Hsp70 expression levels and the induction of their autoantibodies in NMSC, especially skin SCC and BCC, needs to be further validated in a future study.

Mitsui et al. had observed that the upregulation of MMP-7 mRNA in skin invasive SCC driven by IL-24 might enhance the proliferation, migration, and invasion of skin SCC cells [42]. However, in this study, the public data from Oncomine showed that there was no significant difference in the expression of MMP-7 mRNA between skin cancers and normal skins. This inconsistency might result from the small sample size of the obtained data. Thus, whether the mechanism of the production of the MMP-7 autoantibody is correlated to its high expression of gene needs to be further explored.

There were several important shortcomings that we were unable to control. First, as the sample size was small from Oncomine, it would be better to collect the related skin cancer tissues and normal tissues of our participants to further evaluate p53, MMP-7, and Hsp70 mRNA expression. However, we failed to finish this for the reason that some of the enrolled patients rejected surgery when making treatment decisions. Second, our research was a single-center and small-sample one which needs to be further validated in a future study. Third, as exposure to ultraviolet B irradiation is widely seen as a risk factor of skin cancers [43], it would be better to compare the relationship of excessive exposure to sunshine and our autoantibody panel. If this work was completed in the future, it would further supplement the...
mechanism of skin tumorigenesis and ultraviolet B irradiation. Finally, due to the lack of follow-up data, we were unable to assess the prediction value of these autoantibodies in the prognosis of skin SCC and BCC. Actually, whether tumor-associated autoantibodies could be used as prognostic markers is still controversial and needs further clarification. Autoantibody against p53 has most extensively been studied with regard to its prognostic value. Most studies suggested that autoantibodies against p53 might be associated with tumor prognosis, like ovarian and esophageal cancers [44, 45]. On the contrary, several studies showed that the prognostic value of the p53 autoantibody for the overall survival prediction is limited [46]. For autoantibodies against MMP-7 and Hsp70, there are relatively few studies on tumor prognosis. Only one study indicated that the MMP-7 autoantibody might be a novel prognostic biomarker for oral squamous cell carcinoma [19]. A few studies found that positivity for the Hsp70 autoantibody tended to have a worse prognosis in cancer patients [47]. Based on the abovementioned evidences, we suppose that such autoantibodies might be associated with the prognosis with NMSC, which needs to be verified in future work.

5. Conclusions
In summary, we utilized ELISA to detect the serum levels of three autoantibodies in patients with skin SCC and BCC and compared it with normal controls. The high levels were observed, as well as the high diagnostic value, especially in early-stage skin cancers. The RNA-seq public data from Oncomine revealed significant upregulation of p53 mRNA in BCC and Hsp70 mRNA in SCC. Taken together, our current findings could benefit future studies in targeting this serum panel for the screening of NMSC.

Data Availability
The data used to support the findings of this study are available from the corresponding authors upon request.
Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Shi-Han Yang and Can-Tong Liu contributed equally to this work.

Acknowledgments

This work was supported by funding from the Medical Project of Science and Technology Planning of Shantou (grant number 181203204010504), the 2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant (grant number 2020LKSFG018), and the Science and Technology Special Fund of Guangdong Province of China (grant numbers 190829105556145 and 180918114960704).

References

[1] G. T. Bowden, "Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling," Nature Reviews. Cancer, vol. 4, no. 1, pp. 23–35, 2004.
[2] K. K. Youssef, A. Van Keymeulen, G. Lapouge et al., "Identification of the cell lineage at the origin of basal cell carcinoma," Nature Cell Biology, vol. 12, no. 3, pp. 299–305, 2010.
[3] M. C. Cameron, E. Lee, B. P. Hibler et al., "Basal cell carcinoma: contemporary approaches to diagnosis, treatment, and prevention," Journal of the American Academy of Dermatology, vol. 80, no. 2, pp. 321–339, 2019.
[4] I. Marciil and R. S. Stern, "Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis," Archives of Dermatology, vol. 136, no. 12, pp. 1524–1530, 2000.
[5] S. K. T. Que, F. O. Zwald, and C. D. Schults, "Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging," Journal of the American Academy of Dermatology, vol. 78, no. 2, pp. 237–247, 2018.
[6] P. Costa-Pinheiro, D. Montezuma, R. Henrique, and C. Jeronimo, "Diagnostic and prognostic epigenetic biomarkers in cancer," Epigenomics, vol. 7, no. 6, pp. 1003–1015, 2015.
[7] E. M. Tan and J. Zhang, "Autoantibodies to tumor-associated antigens: reporters from the immune system," Immunological Reviews, vol. 222, no. 1, pp. 328–340, 2008.
[8] L. Dai, J. C. Tsay, J. Li et al., "Autoantibodies against tumor-associated antigens in the early detection of lung cancer," Lung Cancer, vol. 99, pp. 172–179, 2016.
[9] R. T. Fortner, A. Dannans-Machado, and R. Kaaks, "Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection," Gynecologic Oncology, vol. 147, no. 2, pp. 465–480, 2017.
[10] Y. W. Xu, C. T. Liu, X. Y. Huang et al., "Serum autoantibodies against STIP1 as a potential biomarker in the diagnosis of esophageal squamous cell carcinoma," Disease Markers, vol. 2017, Article ID 5384091, 9 pages, 2017.
[11] H. Chen, S. Werner, S. Tao, I. Zornig, and H. Brenner, "Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer," Cancer Letters, vol. 346, no. 2, pp. 178–187, 2014.
[12] M. G. Bouwhuis, S. Suciu, S. Collette et al., "Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon," Journal of the National Cancer Institute, vol. 101, no. 12, pp. 869–877, 2009.
[13] H. Gogas, J. Ioannovich, U. Dafni et al., "Prognostic significance of autoimmunity during treatment of melanoma with interferon," The New England Journal of Medicine, vol. 354, no. 7, pp. 709–718, 2006.
[14] R. M. Duvoisin, G. Ren, T. L. Haley, M. H. Taylor, and C. W. Morgans, "TRPM1 autoantibodies in melanoma patients without self-reported visual symptoms," Investigative Ophthalmology & Visual Science, vol. 60, no. 6, pp. 2330–2335, 2019.
[15] L. V. Crawford, D. C. Pim, and R. D. Bulbrook, "Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer," International Journal of Cancer, vol. 30, no. 4, pp. 403–408, 1982.
[16] R. Lubin, G. Zalcman, L. Bouchet et al., "Serum p53 antibodies as early markers of lung cancer," Nature Medicine, vol. 1, no. 7, pp. 701–702, 1995.
[17] Y. W. Xu, Y. H. Peng, R. Chen et al., "Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma," The American Journal of Gastroenterology, vol. 109, no. 1, pp. 36–45, 2014.
[18] C. C. Wu, Y. T. Chang, K. P. Chang et al., "Salivary autoantibodies as noninvasive diagnostic markers of oral cavity squamous cell carcinoma," Cancer Epidemiology, Biomarkers & Prevention, vol. 23, no. 8, pp. 1569–1578, 2014.
[19] T. Jiang, P. Xie, and H. Liu, "Circulating anti-matrix metalloproteinase-7 antibodies may be a potential biomarker for oral squamous cell carcinoma," Journal of Oral and Maxillofacial Surgery, vol. 74, no. 3, pp. 650–657, 2016.
[20] R. Rucksaken, C. Pairojkul, P. Pinlaor et al., "Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma," PLoS One, vol. 9, no. 7, article e103259, 2014.
[21] S. G. Keohane, C. M. Proby, C. Newlands et al., "The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K.," The British Journal of Dermatology, vol. 179, no. 4, pp. 824–828, 2018.
[22] A. I. Riker, S. A. Enkemann, O. Fodstad et al., "The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis," BMC Medical Genomics, vol. 1, no. 1, p. 13, 2008.
[23] C. Mohr, A. Moysan, R. Lubin et al., "Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies," British Journal of Cancer, vol. 85, no. 12, pp. 1883–1886, 2001.
[24] Y. W. Xu, H. Chen, H. P. Guo et al., "Combined detection of serum autoantibodies as diagnostic biomarkers in esophagealgastric junction adenocarcinoma," Gastric Cancer, vol. 22, no. 3, pp. 546–557, 2019.
[25] K. S. Anderson, J. Wong, A. Vitosin et al., "p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer," Cancer Epidemiology, Biomarkers & Prevention, vol. 19, no. 3, pp. 859–868, 2010.
[26] R. Villar-Vazquez, G. Padilla, M. J. Fernandez-Acenero et al., "Development of a novel multiplex beads-based assay for
autoantibody detection for colorectal cancer diagnosis,” *Proteomics*, vol. 16, no. 8, pp. 1280–1290, 2016.

[27] Y. H. Peng, Y. W. Xu, L. S. Huang et al., “Autoantibody signatures combined with Epstein-Barr virus capsid antigen-Î²G as a biomarker panel for the detection of nasopharyngeal carcinoma,” *Cancer Prevention Research (Philadelphia, Pa.)*, vol. 8, no. 8, pp. 729–736, 2015.

[28] C. Qi, P. Wang, B. Wang et al., “Establishment and validation of an immunodiagnostic model for prediction of breast cancer,” *Oncoimmunology*, vol. 9, no. 1, p. 1682382, 2020.

[29] M. Sumazaki, H. Ogata, Y. Nabeysa, A. Kuwajima, T. Hiwasa, and H. Shimada, “Multipanel assay of 17 tumor-associated antibodies for serological detection of stage 0/1 breast cancer,” *Cancer Science*, vol. 112, no. 5, pp. 1955–1962, 2021.

[30] S. Yajima, T. Suzuki, Y. Oshima et al., “New assay system Elecsys Anti-p53 to detect serum anti-p53 antibodies in esophageal cancer patients and colorectal cancer patients: multi-institutional study,” *Annals of Surgical Oncology*, 2020.

[31] J. H. Zhou, B. Zhang, K. H. Kernstine, and L. Zhong, “Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma,” *World Journal of Gastroenterology*, vol. 17, no. 10, pp. 1373–1378, 2011.

[32] L. Zhong, X. Peng, G. E. Hidalgo, D. E. Doherty, A. J. Stromberg, and E. A. Hirschowitz, “Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients,” *Cancer Detection and Prevention*, vol. 27, no. 4, pp. 285–290, 2003.

[33] Y. Y. Zhou, J. Zhou, T. G. Lim, and M. C. Chung, “Serum autoantibodies as biomarkers for early cancer detection,” *The FEBS Journal*, vol. 276, no. 23, pp. 6880–6904, 2009.

[34] J. Y. Zhang, “Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis,” *Cancer Detection and Prevention*, vol. 28, no. 2, pp. 114–118, 2004.

[35] P. D. Wagner, M. Verma, and S. Srivastava, “Challenges for biomarkers in cancer detection,” *Annals of the New York Academy of Sciences*, vol. 1022, no. 1, pp. 9–16, 2004.

[36] D. L. Albertus, C. W. Seder, G. Chen et al., “AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma,” *Journal of Thoracic Oncology*, vol. 3, no. 11, pp. 1236–1244, 2008.

[37] Y. Q. Tong, B. Liu, H. Y. Zheng et al., “BMI-1 autoantibody as a new potential biomarker for cervical carcinoma,” *PLoS One*, vol. 6, no. 11, article e27804, 2011.

[38] C. Desmetz, C. Bascomb-Mollevi, P. Rochaix et al., “Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women,” *Clinical Cancer Research*, vol. 15, no. 14, pp. 4733–4741, 2009.

[39] J. Wood, M. Pring, J. W. Eveson, N. Price, C. M. Proby, and A. Hague, “Co-overexpression of Bag-1 and heat shock protein 70 in human epidermal squamous cell carcinoma: Bag-1-mediated resistance to 5-fluorouracil-induced apoptosis,” *British Journal of Cancer*, vol. 104, no. 9, pp. 1459–1471, 2011.

[40] M. Boysen, R. Kityk, and M. P. Mayer, “Hsp70- and Hsp90-mediated regulation of the conformation of p53 DNA binding domain and p53 cancer variants,” *Molecular Cell*, vol. 74, no. 4, pp. 831–843.e4, 2019, e4.

[41] V. Dahiya, G. Agam, J. Lawatscheck, D. A. Rutz, D. C. Lamb, and J. Buchner, “Coordinated conformational processing of the tumor suppressor protein p53 by the Hsp70 and Hsp90 chaperone machineries,” *Molecular Cell*, vol. 74, no. 4, pp. 816–830.e7, 2019, e7.